Healthcare Stock Ratings
Analysts Maintain Bullish Ratings Across Major Healthcare And Smaller Biotech Stocks
Anonymous
Key Points
1
Cigna’s consensus rating was Moderate Buy, with an average target of $338.56, implying 22.7% upside; Morgan Stanley separately maintained a Buy rating with a $361 target.
2
Wave Life Sciences had a Strong Buy consensus and an average target of $18.27. Ladenburg Thalmann had also recently initiated coverage with a Buy rating and a $10 target.
3
For Syndax, Citi maintained a Buy rating but set a $57 target—well above the $37.33 consensus target—while H.C. Wainwright’s target was $38.
4
The Kura Oncology Buy rating came from J.P. Morgan analyst Priyanka Grover, whose TipRanks profile showed a 15% success rate and an average return of -26.8%; Bank of America also maintained a Buy rating, with a $31 target.
Healthcare analysts are painting an upbeat picture across the sector, maintaining Buy ratings on eight stocks including major players Cigna and AbbVie alongside smaller biotech names like Wave Life Sciences and Kura Oncology. Business Insider reported that these bullish assessments highlight particularly large projected upside for smaller biotech names, with some analysts seeing 50% or more potential gains from current levels.
Cigna and Large-Cap Healthcare Gain Analyst Support
Cigna holds a Moderate Buy consensus rating with an average price target of $338.56, implying 22.7% upside from recent trading levels according to analyst data. Morgan Stanley separately maintained its own Buy rating with a $361 target, suggesting the investment bank sees even stronger potential for the major health insurance company.
Wave Life Sciences Earns Strong Buy From Multiple Analysts
Wave Life Sciences has attracted a Strong Buy consensus rating with an average price target of $18.27, representing substantial upside potential according to analyst ratings. Ladenburg Thalmann recently initiated coverage with a Buy rating and a $10 target, though this estimate falls below the broader consensus, suggesting varied views on the biotech's near-term trajectory.
Smaller Biotech Stocks Show Biggest Analyst Upside
Syndax Pharmaceuticals, Pyxis Oncology, and Kura Oncology have attracted Buy ratings with price targets suggesting meaningful gains from current levels. Citi maintained a Buy on Syndax with a $57 target—well above the $37.33 consensus—while H.C. Wainwright set a $38 target. J.P. Morgan analyst Priyanka Grover initiated Buy coverage on Kura Oncology with a $31 target, though her historical track record shows a 15% success rate and average return of -26.8%.
Comparison Metrics Favor Zevra and Certara
In stock comparisons, Zevra Therapeutics outperformed Vireo Growth on 12 of 15 measures, with analysts seeing substantial upside potential despite Vireo trading at a lower valuation according to analysis. Certara also outperformed Health Catalyst on 10 of 15 factors, posting higher revenue and earnings plus a lower price-to-earnings ratio, though Health Catalyst maintained stronger institutional and insider ownership.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
6
Reach
25
A
AnonymousAuthor
